Combination therapy with von Willebrand factor concentrate plus recombinant factor VIII during cesarean section in a patient with type 3 von Willebrand disease and a low inhibitor titer: a case report
暂无分享,去创建一个
K. Amano | K. Fukutake | E. Kinai | K. Shinozawa | T. Hagiwara | M. Bingo | Yushi Chikasawa | Ayano Mitsuhashi | Shigeru Kikuchi
[1] J. Thachil,et al. Management of pregnancy in type 3 von Willebrand disease with alloantibodies , 2018, British journal of haematology.
[2] M. Franchini,et al. Alloantibodies in von Willebrand Disease , 2017, Seminars in Thrombosis and Hemostasis.
[3] C. Leissinger,et al. Acquired hemophilia A: Updated review of evidence and treatment guidance , 2017, American journal of hematology.
[4] S. Skov,et al. Non‐genetic risk factors in haemophilia A inhibitor management – the danger theory and the use of animal models , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.
[5] J. Oldenburg,et al. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A , 2016, Thrombosis and Haemostasis.
[6] R. Tait,et al. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology , 2014, British journal of haematology.
[7] P. Mannucci,et al. Alloantibodies in von Willebrand disease. , 2013, Blood.
[8] A. Biswas,et al. Mutation distribution in the von Willebrand factor gene related to the different von Willebrand disease (VWD) types in a cohort of VWD patients , 2012, Thrombosis and Haemostasis.
[9] H. Platokouki,et al. The challenging management of a child with type 3 von Willebrand disease and antibodies to von Willebrand factor , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.
[10] R. Zotz,et al. Use of Recombinant Factor VIIa in Inherited and Acquired von Willebrand Disease , 2009, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[11] M Morfini,et al. Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.
[12] M. Wolf,et al. Multi‐therapeutic approach to manage delivery in an alloimmunized patient with type 3 von Willebrand disease , 2003, Journal of thrombosis and haemostasis : JTH.
[13] A. Houllier,et al. Mapping and Functional Studies of Two Alloantibodies Developed in Patients with Type 3 von Willebrand Disease , 2000, Thrombosis and Haemostasis.
[14] J. Batlle,et al. Alloantibody from a patient with severe von Willebrand disease inhibits von Willebrand factor-FVIII interaction , 1997, Annals of Hematology.
[15] A. Federici,et al. Posttransfusion anaphylactic reactions in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor. , 1995, The Journal of laboratory and clinical medicine.
[16] A. Federici,et al. Antibodies to von Willebrand factor in von Willebrand disease. , 1995, Advances in experimental medicine and biology.
[17] P. Mannucci,et al. Life‐threatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factor , 1987, European journal of haematology.
[18] P. Mannucci,et al. Antibodies to factor VIII-von Willebrand factor in congenital and acquired von Willebrand's disease. , 1984, Progress in clinical and biological research.
[19] P. Mannucci,et al. Familial incidence of precipitating antibodies in von Willebrand's disease: a study of four cases. , 1979, The Journal of laboratory and clinical medicine.
[20] Letter: A more uniform measurement of factor VIII inhibitors. , 1975, Thrombosis et diathesis haemorrhagica.